GMP News and Research

RSS

Gene therapy transforms life for men with severe form of hemophilia B

Gene therapy developed at St. Jude Children's Research Hospital, University College London and the Royal Free Hospital has transformed life for men with a severe form of hemophilia B by providing a safe, reliable source of the blood clotting protein Factor IX that has allowed some to adopt a more active lifestyle, researchers reported.

19 Nov 2014

China Pharma’s revenues decrease $5.5M to 31% in third quarter 2014

China Pharma Holdings, Inc. (NYSE MKT: CPHI) ("China Pharma" or the "Company"), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced its financial results for the three months ended September 30, 2014.

14 Nov 2014

BioCision announces ThawSTAR™ automated sample thawing system

BioCision, LLC, a leader in advanced products to improve biospecimen handling and standardization, today announced the availability of ThawSTAR™ automated sample thawing system, a breakthrough technology that addresses the “last mile” in the cryopreservation process. Utilizing the patent-pending STAR™ adaptive sensing technology for rapid and standardized thawing and recovery of cells and other biospecimens, ThawSTAR system tailors the thaw cycle to the specific characteristics of each frozen sample.

12 Nov 2014

NCI supports further clinical development of next-generation HPV vaccine

The National Cancer Institute in the USA is supporting the new vaccine developed at the MedUni Vienna against the human papillomavirus (HPV) with at least US$ 3.5 million. This is a major success for the developers and means that the foundations can now be laid for the clinical trials needed for licensing as a vaccine.

30 Oct 2014

TxCell demonstrates therapeutic potential of Col-Treg for treatment of autoimmune uveitis

TxCell SA, a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that TxCell researchers have achieved positive results for Col-Treg, its second product candidate from its ASTrIA platform, in a model of autoimmune uveitis, a leading cause of blindness with very limited treatment options.

28 Oct 2014

GE Healthcare’s advances in imaging quantitation may help clinicians diagnose disease earlier

GE Healthcare shares a suite of advances in imaging quantitation that may help clinicians diagnose disease earlier, deliver more personalised treatment and speed up care at the 27th annual meeting of the European Association of Nuclear Medicine (EANM), 18-22 October, in Gothenburg.

21 Oct 2014

Molecular diagnostics and blood screening systems: an interview with Dr Bos and Dr Koppelman

Screening blood donations and molecular diagnostics for patients started in the nineties. At the beginning, the level of automation in molecular diagnostic testing was limited; most of the work had to be done manually.

12 Oct 2014

TxCell to highlight development, progress of ASTrIA platform at 13th Annual BIO Investor Forum

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today Damian Marron, CEO, TxCell will be presenting at the 13th Annual BIO Investor Forum, October 7-8, 2014 at the Palace Hotel in San Francisco, California, US.

3 Oct 2014

Tianyin Pharmaceutical's Qionglai Facility completes official GMP site visit by CFDA

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), today announced that its Qionglai Facility (QLF) has successfully completed the official site visit by the China Food & Drug Administration's (CFDA) for its Good Manufacturing Practice (GMP) certification.

29 Sep 2014

Bioniche Life Sciences announces year-end results for fiscal 2014, provides corporate update

Bioniche Life Sciences Inc. today announced financial results for its fiscal year ended June 30, 2014.

27 Sep 2014

European GMP certification awarded to Ajinomoto Althea

Ajinomoto Althea, Inc. ("Althea"), a leading provider of biopharmaceutical contract development and manufacturing services announced today that it has officially received its European GMP certificate issued by the Medicines and Healthcare products Regulatory Agency (MHRA).

3 Sep 2014

Scientists identify developmental on-off switch for Streptomyces

Scientists have identified the developmental on-off switch for Streptomyces, a group of soil microbes that produce more than two-thirds of the world's naturally derived antibiotic medicines.

30 Aug 2014

China Pharma Holdings' Q2 2014 revenue decreases by 24% to $6.1 million

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced its financial results for the three months ended June 30, 2014.

15 Aug 2014

TxCell announces launch of POSITIVE project to automate manufacturing process for Ovasave

TxCell SA, a biotech developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, announces today the launch of, and funding awarded to, the POSITIVE project in collaboration with the Gene and Cell therapy Unit (UTCG) developing new antiviral cell-based immunotherapies and Biosafe, a Swiss private company, a developer of innovative solutions for cell processing.

4 Jul 2014

Scientists produce drug compound with potential to block HIV transmission in women

Scientists at the University of Nebraska-Lincoln College of Engineering's Biological Process Development Facility have successfully produced a drug compound with potential to block HIV transmission in women.

4 Jul 2014

Eurofins Genomics, AmpTec sign co-marketing agreement for IVT-RNAs

Eurofins Genomics, international market leader in genomic services, and AmpTec, internationally recognized provider of RNA technology products, have agreed on non-exclusively co-marketing AmpTec's IVT-RNAs globally.

2 Jul 2014

Delphi Genetics announces new license agreement for use of StabyExpress technology in food industry

Delphi Genetics SA has announced today a new license agreement for the use of the StabyExpress® technology in the food industry. The technology will be used for the production of enzymes for food processing.

17 Jun 2014

TxCell receives Certificate of GMP compliance for cell therapy manufacturing facility in France

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it has been granted Certificate of Good Manufacturing Practice (GMP) compliance for its cell therapy manufacturing facility in Besançon, France.

12 Jun 2014

QPharma advises sterile pharmacy compounders to comply with new GMP regulations

QPharma, Inc. is advising sterile pharmacy compounders to be aware of their need to comply with new Good Manufacturing Practices (GMP) regulations.

31 May 2014

Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

A drug's half-life indicates how long a substance will remain active in the body. It is essentially the period of time that it takes for the concentration of the amount of the drug to be reduced by half, and therefore, determines how frequently a drug needs to be administered to maintain its therapeutic effect.

27 May 2014